Brief: Immunicum Updates On Survival Data From Phase II Mereca Trial Of Ilixadencel In Kidney Cancer
18/08/2020 07:09
Aug 18 (Reuters) - Immunicum AB IMMUN.ST :
* ANNOUNCES UPDATE ON SURVIVAL DATA FROM PHASE II MERECA TRIAL OF ILIXADENCEL IN KIDNEY
CANCER
* MEDIAN OVERALL SURVIVAL (OS) WAS REACHED AT 25 MONTHS IN CONTROL GROUP TREATED WITH
SUNITINIB
* FINAL MEDIAN OS VALUE IN ILIXADENCEL TREATMENT GROUP HAS NOT YET BEEN REACHED, INDICATING
A
SURVIVAL BENEFIT IN STUDY'S CO-PRIMARY ENDPOIN
* AUGUST 2020 DATA CONTINUE TO SHOW A SEPARATION IN SURVIVAL CURVES IN FAVOR OF ILIXADENCEL
GROUP
AS PROJECTED BY KAPLAN-MEIER CURVES IN PREVIOUS SURVIVAL FOLLOW-UPS
* FOLLOW-UP ON SURVIVAL DATA WILL BE COLLECTED AND UPDATED CONTINUOUSLY AT 6-MONTH
INTERVALS, WITH
NEXT UPDATE EXPECTED IN Q1 2021
Source text for Eikon: ID:nGNE83kr5C
Further company coverage: IMMUN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))